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Editor's Preface
Following the success of the rst edition of the workshop on Articial Intelligence for Diabetes
(AID) held in The Hague, on 2016, under the umbrella of the ECAI conference, we are very proud
to present its second edition at the AIME conference.
The workshop starts with an invited talk, which will provide an overview of the utilisation of
Articial Intelligence (AI) in diabetes with a particular focus on gestational diabetes. It continues
with regular presentations carried out by people from up to six dierent countries, including UK,
Spain, Italy, USA, Switzerland and Colombia. The afternoon is dedicated to strengthening the
research relationships within the community.
On this occasion, the workshop organization takes a step forward to boost the research commu-
nity by presenting the website ai4diabetes.org. The purpose of this website is to share the results
and advances in the management of diabetes using AI techniques. This will enhance progress
in the eld by establishing synergies among researchers, as well as being a reference point for
various stakeholders including users' associations and companies. We therefore warmly invite all
researchers working in this eld to join.
We hope that you enjoy the workshop and join ai4diabetes.org.
The Organizing Committee
Pau Herrero (Imperial College of London, UK)
Beatriz Lopez (University of Girona, Spain)
Clare Martin (Oxford Brookes University, UK)
Vienna, Austria June 24th, 2017
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Keynote
Artificial Intelligence in Diabetes Care: The
Challenge of Supporting Patients in Their Daily
Living
M. Elena Hernando
Profesora Titular / Associate Professor
Grupo de Bioingenieria y Telemedicina, ETSI Telecomunicacion, Universidad
Politecnica de Madrid, Avda Complutense 30, 28040 Madrid, Spain
Abstract. Diabetes is a complex disease where healthcare professionals
and patients have to work together to achieve a good metabolic control.
Patients play an active role in their own care and need to have the knowl-
edge to make decisions adapted to their daily living. In such scenario,
AI applications make possible to support patients decisions at any sce-
nario of their daily living and additionally they open the door to react at
time scales smaller than the programmed face-to-face visits times. In the
past decade, the diabetes management paradigm is being transformed
by the combination of continuous glucose monitoring and insulin pump
data. Additionally, current wearable technologies allow to monitor other
physiological parameters (i.e. heart rate, sleep quality, physical activity,
etc) that have a close relationship with metabolic control. Nowadays, the
challenge is to create proactive AI systems, integrated in the healthcare
information systems, accessible from patients devices and able to collect
relevant multi-parametric data from patients in a seamless way. Aspects
as user interfaces design and user modelling play a crucial role in the
success of users interaction with AI systems. This talk will discuss the
lessons learned in previous experiences and projects and will present new
opportunities for AI in diabetes.
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Automatic Adjustment of Basal Insulin Infusion Rates in 
Type 1 Diabetes using Run-to-Run Control and Case-
Based Reasoning 
Pau Herrero1, Peter Pesl1, Monika Reddy2, Nick Oliver2 and Pantelis Georgiou1 
1Centre for Bio-Inspired Technology, Imperial College London, London, SW7 2AZ, UK 
2Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, W2 1NY, UK 
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Abstract. People with type 1 diabetes mellitus rely on a basal-bolus insulin 
regimen to roughly emulate how a non-diabetic person’s body delivers insulin. 
Adjusting such regime is a challenging process usually conducted by an expert 
clinical. Despite several guidelines exist for such purpose, they are usually 
impractical and fall short in achieving optimal glycemic outcomes. Therefore, 
there is a need for more automated and efficient strategies to adjust such regime. 
This paper presents, and in silico validates, a novel technique to automatically 
adapt the basal insulin profile of a person with person with type 1 diabetes. The 
presented technique, which is based on Run-to-Run control and Case-Based 
Reasoning, overcomes some of the limitations of previously proposed 
approaches and has been proved to be robust in front of realistic intra-day 
variability. Over a period of 5 weeks on 10 virtual adult subjects, a significant 
reduction on the percentage of time in hyperglycemia (<70mg/dl) (from 14.3±5.6 
to 1.6±1.7, p< 0.01), without a significant increase on the percentage of time in 
hypoglycemia (>180mg/dl) (from 10.2±5.9 to 1.6±1.7, p=0.1), was achieved.
  
Keywords: Diabetes management, insulin therapy, artificial intelligence, case-
based reasoning, run-to-run control.  
1 Introduction 
Type 1 diabetes mellitus (T1DM) is an autoimmune condition characterized by elevated 
blood glucose levels due to the lack of endogenous insulin production [1]. People with 
T1DM require exogenous insulin delivery to regulate glucose. Current therapies for 
T1DM management include the administration of multiple daily injections (MDI) or 
continuous subcutaneous insulin infusion (CSII) with pumps. 
A basal-bolus insulin regimen involves taking a longer acting form of insulin to keep 
blood glucose levels stable through periods of fasting and separate injections of shorter 
acting insulin to prevent rises in blood glucose levels resulting from meals. Such 
regimen attempts to roughly emulate how a non-diabetic person’s body delivers insulin. 
People with T1DM using insulin pumps are able to pre-program different infusion rates 
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along the day, hence they are able to achieve a finer control [2].  Fig. 1 shows an 
example of the plasma insulin profile of a typical MDI basal-bolus regimen. 
 
 
Fig. 1. Plasma insulin profile of a typical basal-bolus regimen. Dashed lines correspond to meal 
bolus and solid line to the basal insulin injection. 
Several medical guidelines exist for adjusting insulin doses basal-bolus regime 
[3][4], which usually require a cumbersome process of trial and error conducted by an 
expert clinical. In addition, this regimen is not static and changes over the time due 
circadian variation in hormone levels (e.g. dawn phenomenon), physical exercise, 
psychological stress, recurrent illness, or long-term changes in insulin sensitivity due 
to lifestyle (e.g. obesity) [1]. Therefore, there is a need for more automated and efficient 
strategies to adjust such regime. 
2 Related Work 
In order to automatically adjust the basal insulin regimen of a pump, Palerm et al. 
proposed a Run-to-Run control algorithm that requires six capillary blood glucose 
measurements along the day at specific times [5]. However, this approach might be 
impractical in a real-life scenario due to the numerous capillary measurements required.    
In the context of an artificial pancreas (i.e. hybrid closed-loop control), a Run-to-
Run approach which adapts the basal insulin delivery during the night and the 
carbohydrate-to-insulin ratio during the day, based on some performance indices 
calculated from subcutaneous continuous glucose sensor data has been proposed by 
Toffanin et al. [6]. 
It is important to note that, apart from considering intra-day changes in insulin 
sensitivity due to circadian variations of hormonal levels, none of these approaches take 
into consideration the variability on insulin requirements due to other factors such as 
physical exercise, alcohol, stress or menstrual cycle. 
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3 Methods 
In this paper, we present a novel technique to automatically adjust the basal insulin 
profile of a person with type 1 diabetes. For this purpose, a Run-to-Run algorithm [7] 
incorporating a new control law, which avoids some of the limitations of previously 
proposed techniques, is introduced (e.g. number of capillary measurements). Then, 
Case-Based Reasoning [8] is employed to account for intra-subject insulin sensitivity 
variability. This is done by storing in a subject-specific case-base representing scenarios 
with significantly different insulin requirements (e.g. dinner after exercise vs. dinner 
after watching a movie) and therefore, requiring a different basal insulin dosing. Then, 
a Run-to-Run algorithm is applied to each one of the cases in the case-base in order to 
adapt the solutions (i.e. basal rate) if considered to be suboptimal. 
3.1 Case-Based Reasoning 
Case-Based Reasoning (CBR) is an artificial intelligence problem solving 
framework that solves a newly encountered problem, based on the information obtained 
from previously solved problems and stored as cases in a case-base [8]. A case is 
defined by  
𝐶𝑎𝑠𝑒𝑖 = {𝑃𝑟𝑜𝑏𝑙𝑒𝑚𝑖, 𝑆𝑜𝑙𝑢𝑡𝑖𝑜𝑛𝑖,𝑂𝑢𝑡𝑐𝑜𝑚𝑒𝑖}, (2) 
where Problemi is the description of the problem to be solved (e.g. controlling basal 
glucose); Solutioni is the solution to Problemi (e.g. basal insulin rate); and Outcomei is 
the outcome resulting of applying Solutioni to Problemi (e.g. glucose outcome). 
CBR is usually described in four steps: Retrieve the most similar cases to the problem 
to be solved from the case-base; Reuse the solutions of retrieved cases; Revise the 
outcome of the applied solution to the new problem; and Retain the new problem if its 
solution is considered useful for solving future problems. Figure 4 show the four steps 
of the CBR cycle (Retrieve, Reuse, Revise, Retain) applied to the problem of basal 
insulin dosing. 
 
Figure 4. CBR cycle (Retrieve, Reuse, Revise, Retain) applied to the problem of 
basal insulin dosing  
AID 2017 Proceedings of the 2nd International Workshop on Articial Intelligence for Diabetes (AID)
4
4 
 
In this work, cases are stored in a subject-specific case-base representing scenarios 
with significantly different insulin requirements (e.g. dinner after exercise vs. dinner 
after watching a movie) and therefore, requiring different basal insulin rates.  
Cases are retrieved from the case-base by computing the Euclidian distance between 
the current problem and all the cases in the case-base and by selecting the case with the 
shorter distance.  
If the closest retrieved case is still very distant from the current scenario, its solution 
can be reused (Reuse step) by applying a set of simple rules to guarantee that the applied 
solution is safe (e.g. reduce basal rate by 30%) and a new case is created for the new 
scenario. If the retrieved case is equal to the current scenario, then no new case is 
created. 
In order to perform the Revision step, the R2R algorithm presented below is 
employed, which adapt the solution (i.e. basal rate) of the retrieved, or newly created, 
case when the glucose outcome is considered sub-optimal based on the analysis of the 
postprandial CGM measurements.  
3.2 Run-To-Run control 
Run-To-Run (R2R) is a control methodology designed to exploit repetitiveness in the 
process that is being controlled [7]. Insulin dosing, and in particular basal insulin 
delivery, has a repetitive nature. Therefore, R2R control can be used to exploit such 
characteristic. 
The proposed R2R algorithm is based on the hypothesis that the time of the day-time 
when a person is closest to the fasting condition is right before the meals. Therefore, 
the pre-meal glucose measurement is used to adjust the basal insulin rate of the previous 
post-prandial period. Regarding the night-time period, this is split in two parts, from 
dinner time to 6 hours after dinner and from that time to breakfast time. Note that, unlike 
the six glucose measurements required by the R2R algorithm by Palerm et al. [5], the 
proposed algorithm only requires four.  
The control law used to adjust the basal rates is defined by 
𝐵𝑎𝑠𝑎𝑙𝑖
𝑘+1 = 𝐵𝑎𝑠𝑎𝑙𝑖
𝑘 + 𝐾 · (𝐺𝑖 − 𝐺𝑇),  (1) 
where sub-index i indicates the time interval, the super-index k indicates the 
iteration, K is a tuning gain, Gi is the pre-meal glucose value for corresponding interval, 
and GT is the glucose target.  
It is important to remark that previously proposed R2R algorithms for basal insulin 
adjustment [5][7] are able deal with intra-day variability due circadian variation, but 
are not able to deal with inter-day variability due to other factors such as exercise, 
alcohol, stress, and menstrual cycle. For this purpose, the utilization of Case-Based 
Reasoning [8] has been proposed in this work. 
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4 Experimentation and Results 
4.1 In Silico Evaluation under Intra-Day Variability 
The latest version of the UVa-Padova T1DM simulator (v3.2) [9] was used to 
evaluate the proposed to automatically adapt basal insulin. 10 adult subjects were used 
for this purpose. Basal insulin infusion rates were initialised the one provided by the 
the simulator. Meal boluses were computed using a standard bolus calculator [Schmidt 
2014] using the default parameters provided by the simulator. 
A six-week scenario was selected in order to leave enough time to the basal 
adaptation mechanism to converge. The selected daily pattern of carbohydrate dose 
intake was 7am (60g), 1pm (100g) and 7pm (80g).  
Intra-day variability and uncertainty were introduced in the simulator as described 
by Herrero and colleagues [10]. Note that despite all the variability introduced in the 
simulator, only four different cases were required within the CBR algorithm (i.e. post-
breakfast, post-lunch and post-dinner, and night time).  
The following glycemic metrics, which are widely accepted by the artificial pancreas 
community to evaluate glucose controllers, were selected for comparison purposes: 
mean blood glucose (BG in mg/dl); percentage time in glucose target range [70,180] 
mg/dl (% in T); percentage time below target (i.e. hypoglycemia) (% < T); percentage 
time above target (i.e. hyperglycemia) (% > T); 
4.2 Glycemic Outcomes 
Table 1 shows the results corresponding to the 10 virtual adults after one week of 
no adaptation and at week 6 after 5 weeks of basal adaptation. Fig. 2 shows a weekly 
evolution of three of the evaluated glycemic metrics 
Table 1. Glycemic outcomes corresponding to the 10 virtual adult subjects. 
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Fig. 2. Weekly evolution of the glycemic metrics. Error bars represent the standard deviation. 
 
When analyzing the weekly evolution of the evaluated glycemic metrics, it can be 
observed that glycemic metrics take about 3 weeks to converge without significant 
oscillations towards a steady state value and remain fairly stable along the simulation. 
In a real-life scenario, the convergence rate might take longer due to the 
consideration of more cases representing other scenarios such as exercise, alcohol 
consumption, hormone cycles or stress.  
Clinical trials are required to validate the proposed technique in a real environment. 
Future work includes the evaluation of the presented technique with a meal bolus 
adaptation technique. 
5 Conclusions 
In a virtual T1DM population (10 adults) over a 6-week scenario with intra-day 
variability, the presented basal insulin adaptation technique significantly reduces 
hypoglycemia without a significant increase in hyperglycemia. 
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A CBR-based bolus recommender system for
type 1 diabetes
Ferran Torrent-Fontbona, Beatriz Lopez, and Alejandro Pozo-Alonso
eXiT research group, University of Girona, Girona 17003, Catalunya
Abstract. People with type 1 diabetes mellitus usually need to admin-
ister bolus insulin before each meal to keep the blood glucose level in
the target glycaemic range. However, the factors involved in the calcula-
tion of the appropriate dose can change due to multiple factors and with
an unknown relation. This may increase the error in the bolus calcula-
tion, and therefore, increase the chances of hypoglycaemia and hypergly-
caemia. This paper proposes a bolus recommender system based on case
based reasoning developed under project PEPPER, with the objective
of recommending personalised and adaptive bolus doses. The system has
been tested with in silico adults with UVA/PADOVA T1DM simulator.
Results show that the use of the proposed bolus recommender system
increases the percentage of time in the target glycaemic range.
Keywords: Diabetes, bolus recommender system, case based reasoning,
patient empowerment
1 Introduction
Type 1 diabetes mellitus (T1DM) is a chronic disease, which requires people
with it to check their blood glucose level and administer insulin to themselves
to control and maintain blood glucose in the target range. People with T1DM
usually use two types of insulin: bolus insulin, which is a fast acting insulin,
and basal insulin, which is a slow acting insulin. However, the calculation of
the needed amount of either bolus or basal at each time is not easy and the
parameters to calculate it may change due to several factors. Then, T1DM people
self-regulate, with the help of clinicians every several weeks or months, the needed
doses.
This paper proposes a Case Based Reasoning (CBR) [1] approach to esti-
mate the parameters for bolus calculation and recommend bolus doses. CBR is
a lazy learning methodology [5], which consists of using past experiences to solve
future problems. CBR traditionally incorporates four main main steps [1]: re-
trieve, reuse (or adaptation), revise (or evaluation), and maintenance (or storage
and management of the case base). These consist of (i) identifying prior simi-
lar experiences to the problem to be solved; (ii) adapting the solutions of prior
experiences to find a solution to the new problem; (iii) evaluating the outcome
of the proposed solution and repair it if necessary; and (iv) storing the current
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experience (problem and solution) for further problems and manage the case
base.
There are various commercial applications that facilitate the calculation of
the amount of insulin, usually the bolus dose for a given basal. The author in [2]
provides a wide review of the current applications for bolus calculation. How-
ever, these applications require the user to estimate the needed parameters to
calculate the bolus, such as the insulin to carbohydrates ratio (ICR) besides the
amount of carbohydrates. Moreover, these parameters may change due to differ-
ent factors and without a known relation. This usually makes these applications
very ineffective.
Nevertheless the literature presents approaches capable to iteratively adjust
some of the parameters for bolus calculation. In this regard, D. Brown presents in
[2] a bolus calculator approach based on Case Based Reasoning (CBR) [1], which
considers carbohydrate intakes, preprandial blood glucose levels of a few previous
meals in order to calculate the appropriate bolus. Conversely, this paper does not
consider previous meals and the implementation of the CBR steps are different.
Shashaj et al. propose in [6] a run-to-run algorithm [9] instead of a CBR, to
iteratively adjust bolus calculator parameters. The point of using a CBR is
to have different parameters’ values for different situations. The authors in [3,4]
combine a run-to-run algorithm and a CBR of prototypes to iteratively select and
adjust the parameters of a bolus calculator depending on the context (time of day
and physical activity). The revise step of CBR approach presented in this paper
is based on the one presented in [3]. However, the proposed revise methodology
presents some modifications (see Section 2.3). Moreover, the proposed retrieve,
reuse and maintenance steps differ from [3], since the proposed approach is not a
CBR of prototypes and, therefore, the size of case base can dynamically change
according to the attributes of the cases.
Following this line of research, PEPPER (Patient Empowerment through
Predictive PERsonalised decision support) project has the objective of providing
a personalised adaptive decision support system for bolus dosing that combines
multiple data sources. This paper presents a CBR-based bolus recommender
system for T1DM and analyses its performance with UVA/PADOVA T1DM
simulator [7].
2 CBR-based bolus recommender system
The CBR-based bolus recommender system presented in this paper has the ob-
jective of recommending an appropriate bolus dose to people with T1DM before
a meal. In order to do so, the CBR considers a set of attributes that describe
the situation or case, and the insulin to carbohydrates ratio (ICR) of the user
as the solution of the case. Then, this ICR is used to calculate the appropriate
bolus dose for a given amount of carbohydrates. The remainder of the section
explains the implementation of the CBR steps for bolus recommendation.
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2.1 Retrieve
The retrieve step is responsible for selecting similar cases to the query (or new)
case. Retrieve methods usually calculate the distance between the query case
and those in the case base and, then, select the closest ones.
The proposed CBR methodology considers the ICR of the user as the solu-
tion. Therefore, the considered attributes must be variables that can modify the
ICR of a user. These variables include time of day (for intra-day variability),
physical activity, stress, hours of sleep, alcohol ingestion, ambient temperature,
etc. However, there are contextual factors that usually have a great impact on
the ICR, e.g. menstruation and digestive illness. As a consequence the proposed
retrieve methodology consists of two steps: context reasoning and selection. Con-
text reasoning consists of choosing the appropriate contextual case base and se-
lection consists of choosing the closest cases (in the corresponding contextual
case base) to the query case. Note that this retrieve methodology implies that
the CBR system manages not one, but several case bases.
2.2 Reuse
The reuse step consists of adapting the solutions of the retrieved cases to the
query case. This paper proposes a weighted average of the retrieved ICRs using
the distance between the retrieved cases and the query case.
Once the ICR of the query case is derived, the bolus recommendation is
calculated as follows:
B =
CHO
ICR
+
Gc −Gsp
ISF
− IOB (1)
where CHO is the amount of carbohydrates of the meal, Gc is the blood glucose,
Gsp is the standard blood glucose level, ISF is the insulin sensitivity factor and
IOB is the remaining active insulin (insulin on board). ISF is calculated as
stated in [8] using Equation (2), where W is the weight of the user in kg.
ISF =
341.94ICR
W
(2)
2.3 Revise
After the user administers a bolus (e.g. the recommended bolus) and has the
meal, the postprandial phase starts. The proposed revise process is based on the
idea proposed in [3], which relies on the assumption that an additional bolus is
necessary to bring the minimum glucose value, Gmin, in the glycaemic range. The
value Gmin is calculated as expressed in Equation (3) as the minimum glucose
value measured by the continuous glucose monitor Gcgm(t) between t1 time after
the meal time tm and t2 time after tm with t1 < t2, e.g. t1 = 2h and t2 = 6h.
Gmin = min
t∈{tm+t1,tm+t2}
{Gcgm (t)} (3)
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Given the minimum postprandial blood glucose, the ICR is corrected if Gmin
is not in the glycaemic range ([Gl, Gh]). Then, the corrected ICR (ICRc) is
calculated according to Equation (4), where ICRa is the previous ICR used in
Equation (1) and α is the learning rate (e.g. 0.5). However, conversely to [3], the
revise equation incorporates the learning rate α to smooth ICR changes.
ICRc = (1− α)ICRa + α
CHO +
Gc−Gsp
341.94/W
B + IOB +
Gmin−Gsp
ISF
(4)
2.4 Maintenance
The ICR can change over time. An example is the intra-day variability, which
causes some periodicity in the ICR. This is solved by retrieving the appropriate
cases of the case base. However, the ICR could change over time without an
apparent periodicity because the physiology of the patient changes (age, body
weight, etc.). Therefore, the CBR system has to deal with the concept drift
problem. This paper proposes to deal with this problem in the maintenance step
by replacing old cases with new cases if these are similar enough. Therefore, the
proposed retain process is when there is a candidate query case to be stored in
a context case base, check if there is another case within a distance lower than a
particular threshold. In such a case, delete the old case and store the new one.
3 Results
The proposed CBR-based bolus recommended system has been tested on ten
adult in silico subjects using the UVA/PADOVA T1DM simulator [7]. How-
ever, since the simulator does not incorporate intra-day variability of the insulin
sensitivity, this was artificially introduced as proposed in [3].
The performance of the proposed CBR bolus recommender system has been
compared in terms of time with blood glucose in target range (70 mg/dl to 180
mg/dl) with the use of a bolus calculator using Equation (1) and default in silico
subjects’ parameters.
Table 1 shows the average and standard deviation over twenty simulations
of the percentage of time that subjects had blood glucose level in target range
in 90-days simulations. It shows that in silico subjects using the CBR-based
bolus recommender system increase their time in the glycaemic range and, in
average, reduce the standard deviation, meaning that they have a more stable
blood glucose level.
Since the simulation used only considers intra-day variability, the case base
of the recommender system of each subject was formed by only four cases, the
one used to initialise the case base, and another one for each meal (breakfast,
lunch and dinner).
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Table 1. Percentage time in target of eleven in silico adults using the CBR-based
bolus recommender system or a bolus calculator. In bold face those significantly greater
according to Wilcoxon tests, p-value = 0.05.
CBR Bolus calculator
Subject 1 79.49± 2.02 78.33± 5.20
Subject 2 93.43± 2.07 91.15± 1.26
Subject 3 74.95± 2.33 68.87± 4.36
Subject 4 84.76± 5.56 79.02± 10.08
Subject 5 88.84± 4.29 80.60± 7.00
Subject 6 81.91± 1.52 81.18± 2.02
Subject 7 69.68± 6.98 64.10± 6.91
Subject 8 86.87± 1.26 82.61± 5.82
Subject 9 90.18± 2.63 83.92± 3.58
Subject 10 83.03± 4.04 75.24± 7.98
Subject 11 83.26± 4.64 77.63± 5.39
Average 83.31± 3.39 78.51± 5.42
4 Conclusions
People with T1DM need to administer a bolus dose, usually before each meal.
The calculation of the appropriate bolus is not easy and requires the estimation
of a set of parameters, such as the insulin to carbohydrates ratio, that can
change over time due to multiple factors. This paper presents a CBR-based
bolus recommended system which has been developed under project PEPPER.
The objective of the bolus recommender system is to provide personalised and
adaptive bolus recommendations to the users (i.e. people with T1DM).
The system has been tested using eleven in silico adults with the the UVA/
PADOVA T1DM simulator. The results show that the proposed system increases
the percentage of time of subjects’ blood glucose in the glycaemic target range.
Despite the presented results, there is still research to do, especially in the
management of missing data and in the maintenance of the case base.
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Abstract. In this work we describe the application of a Careflow Mining algorithm to detect 
the most frequent careflows from process events. The applied method enriches the detected 
patterns with clinical data to define temporal phenotypes across the studied population. We 
defined a novel approach for dynamically stratifying a population. Novel phenotypes are dis-
covered from heterogeneous data of 424 Italian T2DM patients, and compared in terms of 
metabolic control and complications.  
 
Keywords. Careflow mining, Longitudinal data, Electronic Phenotypes 
Introduction 
A major source of complexity in the management of Type 2 Diabetes (T2DM) pa-
tients arises from the large variability of events they undergo during disease progres-
sion. These events, such as hospital admissions, follow-up clinic visits, laboratory 
tests, and therapy changes, are stored in different data repositories using different 
formats and occurring in temporal sequences that represent the patient careflow [1]. 
Current data management technologies [2] are able to gather and merge data distribut-
ed in Electronic Health Records (EHRs) and in Administrative Data Warehouses 
(DW), and enable the access to large quantities of complex data that can be exploited 
for the management of chronic diseases. The application of longitudinal analysis and 
careflow discovery to these data enables the recognition of hidden temporal patterns, 
population stratification, and phenotypes definition. Careflow mining techniques can 
automatically detect the most frequent temporal patterns from routinely collected 
administrative and/or clinical data. Once identified, the careflows might be exploited 
to identify sub-groups of individuals in large cohorts of patients. Electronic phenotyp-
ing has been defined as the use of EHRs and secondary data to recognize a set of 
clinical conditions and characteristics that define a sub-cohort of patients, which is a 
computable phenotype [3], [4]. Careflow mining techniques can be used as a novel 
approach for electronic phenotyping. Examples of frameworks able to automatically 
extract phenotypes from EHR data are still limited and none of them is able to repre-
sent longitudinal data. While they combine different sources of EHR data, they tackle 
the complexity through rule-based approaches [5], or they rely on semi-supervised 
methods to extract patient narratives, but without explicitly representing temporal 
relations among events [6]. Recent applications [7] have shown the possibility of 
performing accurate predictions of hospital acquired complications as a function of 
healthcare system exposure using temporal clinical data. Yet few works are applied to 
characterize T2DM. Some cross-sectional approaches [8] demonstrate improved per-
formance in using EHR data, when compared to basic covariates. In [9] authors apply 
an high-throughput clinical phenotyping algorithm to recognize T2DM cases and 
controls, and demonstrate the impact of insufficient longitudinal data on the accuracy 
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of an algorithm, thus suggesting careful consideration of temporal aspects in the de-
sign and execution of T2DM phenotyping algorithms. In our previous work [10], we 
define electronic temporal phenotyping by mining careflows, and we show how care-
flow mining (CFM) can be a useful instrument to identify the evolution of clinical 
states over time, across a population of breast cancer patients. In this work we present 
an application of the method implemented in [10] to analyze T2DM evolution, espe-
cially in terms of complications and assessment of metabolic control. Moreover, we 
describe two additional features of the algorithm: (i) a careflow similarity measure 
based on Jaccard similarity and (ii) the possibility of detecting AND splits in a care-
flow. 
 
Methods 
Cohort description and electronic phenotypes approach. To apply the CFM algo-
rithm and detect novel T2DM phenotypes, we considered a cohort of 424 patients 
diagnosed with T2DM after 2004, and currently treated at the Istituti Clinici Scientifi-
ci Maugeri (ICSM) hospital in Pavia, Italy. In this work, we focus on the analysis of 
the administrative data collected on this cohort by the Pavia Local Health Care Agen-
cy (ATS). In particular, on the basis of clinicians’ interests, the algorithm was applied 
to the events patients underwent in the period between the diagnosis of T2DM and the 
first visit at ICSM, thus taking into account patients’ encounters within health care 
facilities other than ICSM, or GPs follow-ups. As a first analysis step, we identified 
the sources of complexity for T2DM patients: (i) T2DM careflows can last for a long 
time (in our case for more than 10 years), (ii) the disease progression pace is slow and 
characterized by relatively frequent modifications (e.g changes in therapies and in the 
frequency of follow ups), (iii) sequences of events are very heterogeneous and influ-
enced by multiple conditions. Phenotypes were extracted from all the procedures 
(ambulatory visit, follow ups and hospitalizations) executed during the considered 
observation window (from diagnosis to first visit at ICSM), previously preprocessed 
in order to obtain a consistent representation. After running the algorithm on these 
data, we focused on the characteristics of the extracted phenotypes to evaluate their 
clinical relevance. Clinical variables were used to enrich the phenotypes and to detect 
if transitions among events were due to meaningful medical episodes or if different 
careflows were associated witht different clinical responses. Qualitative representa-
tions of clinical time series of Glycated Hemoglobin (Hba1c) were used to character-
ize patients’ sub-cohorts, and to understand if the mined paths are reliable drivers for 
phenotypes. 
The CFM algorithm [10] takes into account the temporal nature of the data, explicitly 
including both process and clinical information in a two steps approach. The algo-
rithm mines the most frequent patients’ histories form process events, and illustrates 
the evolution of the disease enriching the histories with clinical information. The use 
of events temporal alignment to recognize similar profiles of patients adds a temporal 
dimension to the electronic phenotype. Its results are represented using a directed 
acyclic graph (DAG) where events are connected through arcs that represent temporal 
connections. T2DM disease progression can be illustrated through paths in the DAG. 
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AND events. The results of the CFM algorithm are DAGs, where events occur in 
sequences, and parallel events are not directly mined during the discovery process. 
Process mining techniques, like the alpha algorithm [11], extract parallel routings if 
sequences like <B, C> and <C, B> are detected. We applied detection strategy in-
spired to the same relations among events, with further restrictions on the moment 
when these sequences occur. Once the histories are mined, the algorithm searches for 
sequences of events in the form <B, C> and <C, B> that occur exactly at the same 
point of the history. When the condition is detected the two sequences are merged and 
represented together as B AND C. The number of patients undergoing the events 
merged into the AND, and in the following event, are summed. Once the AND detec-
tion is performed a possible loss of information can occur, especially in terms of tem-
poral and clinical characteristics of the cohorts. However, this feature could be very 
useful in the case of large data variability: form the electronic phenotyping point of 
view, the number of sub cohorts could can reduced when AND events are recognized.  
Similarity measure. Mining careflows from process data allows precise descriptions 
of patients conditions and treatments [12]. Differently from other approaches, where 
the temporal similarity is exploited during clinical workflows mining [13], the care-
flows extracted from our algorithm represent sequences that are identical in timing and 
sequence of events’ occurrence. We therefore decided to use a similarity measure that 
allows the comparison of temporal phenotypes after the algorithm execution. To this 
end, we exploited the Jaccard similarity coefficient [12]. The Jaccard index is com-
monly used in bioinformatics to compare genes and metabolic pathways [14], [15]. It 
is defined as the size of the intersection divided by the size of the union of the sample 
sets. In our application, the Jaccard similarity coefficient is computed for each pair of 
mined phenotypes, on the basis of the whole set of events patients underwent, not only 
the mined ones. The result is a symmetric NxN matrix, where N is the number of the 
mined frequent histories.  
 
Results 
In this work, the clinical events that we considered are ambulatory procedures, inpa-
tient hospitalizations, short procedure unit (SPU) visits, and drug purchases. Each data 
stream was pre-processed as follows: (i) Ambulatory Procedures were grouped on the 
basis of the taxonomy used at ASL that indicates the ward where procedures have 
been performed; (ii) Hospitalization and SPU Procedures ICD9-CM codes were 
mapped into the first levels of the Clinical Classifications Software (CCS) for ICD-9-
CM [16]; (iii) Drug Purchases, classified on the basis of ATC levels, were filtered in 
order to take into account only treatments for diabetes and further aggregated on the 
basis of clinicians’ suggestions, (iv) T2DM Diagnosis, and First Visit at ICSM are 
extracted from the hospital EHR and used as censoring events. The most frequent 
careflows mined by the algorithm are shown in Figure 1. In this figure, it is possible to 
identify eight phenotypes (Φ1, .., Φ9), Φ7 was excluded as associated with less than 2 
patients. The patients in Φ1 exit from the careflow immediately after diagnosis. Other 
sub-cohorts had one or more laboratory exams before the first visit at the hospital 
(Φ2) or a generic specialist visit into another clinical center (Φ5). Patients identified 
by the careflows Φ3, Φ8, Φ9 experienced one or more radiology procedures after the 
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diagnosis. Patients associated with Φ6 follow either the careflow “Diagnosis ! La-
boratory Exam ! Radiology ! End” or the careflow “Diagnosis ! Radiology ! 
Laboratory Exam ! End”. The event “Laboratory Exam AND Radiology” is detected 
and represented. 
To assess the informative value of the careflow mined from process data, Hba1c val-
ues were selected as the most meaningful biomarkers of T2DM control. When com-
pared with Kruskal-Wallis chi-squared test, Hba1c values results are significantly 
different (p-value << 0.01) between different phenotypes. Φ3 shows the highest value 
of Hba1c in the observed period. Thus, we assumed that Φ3 patients are more compli-
cated, and clinicians spend more efforts in trying to stabilize their metabolic control. 
A first characteristic of these patients is that they have the longest period between the 
diagnosis and the first hospital visit (3.4 years, compared to 1.9 years in the rest of the 
cohort). Also drug purchasing information indicates that these patients receive more 
complex and complete diabetic treatments once they receive hospital care: they start to 
be treated with Glp-1_Analogues, Insulin, Repaglinide and Alpha glucosidase inhibi-
tors. We also studied T2DM complications onset in the different groups. Patients in 
Φ3 show an interesting pattern: they experience more Macrovascular events (Acute 
Myocardial Infarction, Occlusion of Carotid Artery, Stroke) than any other phenotype, 
while these events arise after a longer period (on average 891.25 days after the first 
visit, compared with the mean of the rest of the population that is 758 days). Moreo-
ver, when Φ3 was grouped with the most similar phenotypes on the basis of the Jac-
card similarity (Φ5, Φ6), the Kaplan-Mayer survival curve for Macrovascular events 
suggests a faster worsening of the conditions of these patients. Although the computa-
tion of the total sample size needed to reach a significance of 0.05 and a power of 0.8 
is of 1,023 subjects, compared to the 351 available in the data set. 
 
Fig. 1 The mined careflow.  
 
Discussion 
In this work we described how patients’ management processes can be better investi-
gated through longitudinal heterogeneous data. Carfelow mining approaches illustrate 
the evolution of the disease. Mining careflows through process data allows leveraging 
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on information already well-structured to be represented as event logs, avoiding costly 
procedures of preprocessing the entire corpus of clinical data. Process data trigger 
phenotypes definition through the segmentation of the entire population and search 
space reduction. The patterns mined are the substrate for the additional inferences, 
clinical data are used to enrich and compare specific pathways and prove the medical 
relevance of the automatically extracted phenotypes. The detected temporal patterns 
make possible to reconstruct clinical pathways and estimates metabolic control devia-
tions, which might arise during the process of care. The presented analysis framework 
identifies interesting clusters of patients with similar care histories, allowing patient 
risk profiles to be reassessed accordingly.  
Future efforts will be dedicated to improve the similarity measure, for example 
through the exploitation of Edit distance and OSS measures [17], especially for histo-
ries composed of larger number of events. 
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Introduction 
Within the European funded project Mosaic, ten clinical and technical partners collaborate 
to improve Type 2 Diabetes (T2D) patients’ characterization and to evaluate the risk of 
increasing disease complexity. The aim of the project was to implement a novel approach 
for the management of chronic T2D populations. Multiple databases from hospitals, local 
health care agencies and population studies were the project pillars. Clinical data from 
hospital information systems collected during routine practice, together with data recorded 
for billing purposes, provide an integrated research setting and enable a broader vision of 
individual patients’ histories. One of the main project aims was the discovery of well-
defined drug purchases patterns behaviors derived from administrative data streams. The 
developed method to retrieve drug purchases patterns was integrated as part of a Clinical 
Decision Support System (CDSS), structured as a Dashboard. The CDSS has the capability 
to improves patients’ characterization and provide new insight in the disease evolution 
while combining these findings with clinical time series derived from EHRs. Dashboards 
are capable of merging information from different data sources and provide a visual 
summarized representation of key performance indicators. Their visual properties allow to 
provide summaries of a big volume of data through easy to read color coded graphical 
format in order to deliver an intuitive assessment of complex clinical conditions [1]. CDSS 
structured as dashboards are especially useful to represents temporal patterns and have been 
already used in pharmacotherapy and medication surveillance to enhance cognitive 
recognition of patterns in time [2]–[4].  
Methods 
The analysis of drug purchases data has been performed in the following steps:  
1) Quantification of drug exposure. Each drug purchase is described by its Defined Daily 
Dose (DDD), which allows computing the expected number of therapy days related to that 
purchase. As the information about the actual drug dosages a patient should take was not 
available, drug purchases were used as a proxy for estimating drug intake. Some pharmaco-
epidemiology studies [5]–[7] investigate the impact of drug adherence in the arising of T2D 
acute events and in glycemic control. These works successfully exploit Proportion of Days 
Covered (PDC) measure to assess patient exposure and compliance to specific drug. DDD 
values were used as proxy for the dosing regimen and PDC was exploited for the drug 
exposure analysis. PDC is calculated as the number of days with drug on hand divided by 
the number of days in the specified time interval. The PDC can be multiplied by 100 to 
yield to a percentage. Once the PDC values had been computed, it was possible to extract 
the data necessary to compute indicators and thresholds that show, for each patient, his/her 
behavior in purchasing drugs during the evolution of the disease.  
2) Comparison of patient’s behavior with a reference population. In order to assess if a 
patient does not follow the median behavior of the population we have computed a 
statistical test, i.e. the PDC value of the entire observation period of a patient has been 
compared with the population through a Wilcoxon test. For each patient, and for each of 
the drug purchased, the result of the procedure indicates if the patient behavior was in line 
with the rest of the population (when the p value < 0.05) or if he/she tend to purchase more 
or less of a certain drug.  
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3) Visual analytics for extracting interesting patterns. For each time interval where the 
PDC has been computed, a temporal abstraction (qualitative label) that indicates if the 
quantity of the drug purchased in the period is under or over a certain threshold has been 
graphically represented in the dashboard. In particular, the procedure to calculate the 
thresholds was tailored on the single patient for each of the purchased drug. The 33rd and 
66th percentiles of the PDC was computed for each drug purchased, the value of PDC was 
compared to these thresholds and associated to a label that indicates a behavior that diverge 
form the patient’s standards (over or under purchasing a drug). To give to physicians a 
general indication, when the PDC is in range, the label carries also the information about 
two fixed thresholds of 80% and 100%. The periods during which there are no prescriptions 
are labelled as interruptions. 
Results 
The visual analytics approach exploited to show in the CDSS the purchases of drugs during 
the disease evolution is shown in Figure 1 and Figure 2. 
 
Figure 1. The graphs show drugs’ purchases during the disease evolution. Each purchase is 
quantified with the DDD associated to each active principle. The grey box indicates if the patient 
purchased larger or smaller quantities of the drug (with the arrow pointing up or down) and if this 
difference is significant (with a red or green icon), when compared to other patients that are treated 
with the same drug. 
 
Figure 2. Therapy purchasing behavior graphs illustrate the PDC with a 6-month granularity. For 
each semester, the represented time line indicates through colors and labels the compliance of the 
patients to a certain therapy, on the basis of specific thresholds computed on the basis of his/her 
behavior. OVER labels indicate a value greater than the 66th percentile of the patients, other labels 
indicate the value range of the PDC for the considered period. 
 
The system was evaluated near the Istituti Clinici Scientifici Maugeri hospital (Pavia, Italy) 
following a pre-post approach. The actions of 9 physicians were monitored for three months 
before (on 353 patients) and after (on 353 patients) the introduction of the CDSS. The 
comparison of the collected indicators in the pre and post phase shows a reduction of visits 
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duration, an increasing in the prescription of screening exams and in interventions on the 
physical activity. 
Discussion 
In this work we show how administrative data can be exploited as a population marker. The 
detection of drug consumption patterns allows stratifying the population on the basis of 
subjects’ purchasing attitude. Thanks to the developed approach, physicians have the 
opportunity to use as a proxy of the complexity of clinical conditions the patterns of drug 
purchases. Both the procedures to derive the behavior indicators and the exposure 
thresholds produce results which summarize complex and rich information. The visual 
representation of overloaded information turns the complexity into an opportunity to gain 
insight, conclusions, and to support decision making. 
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L2;iBp2 `2bmHib 7Q` i?2 T`2/B+iBQM Q7
TQbiT`M/BH ?vTQ;Hv+2KBb 7`QK BMbmHBM BMiF2b
M/ +`#Q?v/`i2b, MHvbBb M/ +QKT`BbQM
rBi? bBKmHi2/ /i
6#B2M .m#QbbQM1- LiHB JQ`/MvmF2- "2i`Bx GƦT2x2- M/ JB+?2H
a+?mK+?2`1
1 AaG# ;`QmT- lMBp2`bBiv Q7 TTHB2/ a+B2M+2b q2bi2`M arBix2`HM/
2 2sBh ;`QmT- lMBp2`bBiv Q7 :B`QM
#bi`+iX .B#2iB+ TiB2Mib mbmHHv iF2 BMbmHBM #QHmb `B;?i #27Q`2 2i@
BM;  K2HX  r`QM; /Qb;2 Q7 BMbmHBM Kv H2/ iQ  ?vTQ;Hv+2KBX "2@
BM; #H2 iQ MiB+BTi2 bm+? BMbmHBM@BM/m+2/- TQbiT`M/BH ?vTQ;Hv+2KBb
rQmH/ 2M#H2 r`MBM; Q7 i?2 TiB2Mib #Qmi i?2 `BbF bbQ+Bi2/ rBi? i?2
[mMiBiv Q7 BMbmHBM i?2v `2 THMMBM; iQ iF2X AM i?Bb rQ`F- r2 2tTHQ`2
i?2 72bB#BHBiv Q7 T`2/B+iBM; i?2b2 TQbiT`M/BH ?vTQ;Hv+2KBb #v mbBM;
BM7Q`KiBQM pBH#H2 i T`2@K2H iBK2- bm+? b ;Hm+Qb2 H2p2Hb- THMM2/
BMbmHBM BMiF2b M/ +`#Q?v/`i2b 2biBKiBQMbX 6B`bi- M 2tT2`BK2Mi ?b
#22M /QM2 QM  /ib2i +[mB`2/ QM `2H TiB2Mib- 7Q` r?B+? b2p2`H +Hbb2b
Q7 K+?BM2 H2`MBM; H;Q`Bi?Kb ?p2 #22M i`B2/X h?2 Q#iBM2/ `2bmHib /Q
MQi Qz2` T`2/B+iBQMb i?i `2 mb27mH 2MQm;? iQ +QMbB/2` Mv mb;2 BM `2H@
HB72 TTHB+iBQMbX h?2b2 FBM/b Q7 /ib2ib ě +[mB`2/ QM `2H TiB2Mib ě
bmz2` ?2pBHv 7`QK KBbbBM; /i M/ BM+Q``2+i +`#Q?v/`i2b 2biBKiBQMb
i?Qm;?X AM Q`/2` iQ MHvb2 i?2 BKT+i Q7 i?2b2 ~rb QM i?2 Q#iBM2/
`2bmHib- i?2 bK2 2tT2`BK2Mi ?b #22M `mM QM  bBKmHi2/ /ib2iX _2@
bmHib bmTTQ`i i?i 2p2M rBi? i?2 bBKmHi2/ /ib2i- r?B+? /Q2b MQi ?p2
KBbbBM; /i M/ r?B+? ?b T`2+Bb2 +`#Q?v/`i2b BMiF2- i?2b2 72im`2b
HQM2 `2 MQi #H2 iQ T`2/B+i TQbiT`M/BH ?vTQ;Hv+2KBX h?2`27Q`2- BK@
T`QpBM; i?2 [mHBiv Q7 TiB2Mib MMQiiBQMb Bb MQi 2MQm;? iQ bQHp2 i?2
T`Q#H2K- M/ mbBM; i?2b2 72im`2b rBi?Qmi 7m`i?2` 72im`2b 2M;BM22`BM;
/Q2b MQi Qz2` ;QQ/ `2bmHibX
E2vrQ`/b, >vTQ;Hv+2KB- S`2/B+iBQM- AMbmHBM- *`#Q?v/`i2b
R AMi`Q/m+iBQM
hvT2 A /B#2i2b TiB2Mib mbmHHv iF2 BMbmHBM #QHmb #27Q`2 bi`iBM;  K2HX h?2
/Qb;2 Q7 BMbmHBM /2T2M/b QM i?2 [mMiBiv Q7 +`#Q?v/`i2b i?2v `2 ;QBM; iQ
BM;2bi- M/ i?Bb [mMiBiv Bb mbmHHv 2biBKi2/ #v i?2 TiB2Mib i?2Kb2Hp2bX h?2b2
2biBKiBQMb Kv #2 2``Q` T`QM2- M/ iFBM; iQQ Km+? BMbmHBM Kv H2/ iQ ?vTQ@
;Hv+2KBb r?B+? Kv #2 /M;2`Qmb 7Q` TiB2Mib HBp2b BM i?2 HQM; i2`KX
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AM i?Bb rQ`F r2 2tTHQ`2 i?2 TQbbB#BHBiv Q7 MiB+BTiBM; bm+? TQbiT`M/BH ?v@
TQ;Hv+2KBb #v mbBM; i?2 BM7Q`KiBQM pBH#H2 Dmbi2 #27Q`2  K2H, TiB2MiǶb
;Hv+2KB H2p2Hb- THMM2/ BMbmHBM BMiF2b M/ +`#Q?v/`i2b 2biBKiBQMbX "2BM;
#H2 iQ /Q bQ rQmH/ 2M#H2 r`MBM; Q7 i?2 TiB2Mib #Qmi i?2 `BbF bbQ+Bi2/
rBi? i?2 /Qb;2 Q7 BMbmHBM i?2v `2 THMMBM; iQ iF2X
 #B; T`i Q7 i?2 rQ`F ;QBM; BM i?2 /B`2+iBQM Q7 ?vTQ;Hv+2KBb T`2/B+iBQMb 7Q@
+mb2b QM HBp2 T`2/B+iBQMb 7`QK *QMiBMmQmb :Hm+Qb2 JQMBiQ`BM; U*:JV bB;MHb (R-
k)X aQK2 `2 bT2+BHHv Q`B2Mi2/ iQr`/ TiB2Mib rBi? BMbmHBM TmKTb- b i?2v i`v
iQ /2i2+i r?2M iQ biQT #bH BMbmHBM iQ T`2p2Mi ?vTQ;Hv+2KBb (j- 9)X Pm` rQ`F-
?Qr2p2`- Bb i`;2iBM; /Bz2`2Mi m/B2M+2b M/ Q#D2+iBp2bX h?2 ;QH Bb iQ Qz2`
i?2 TQbbB#BHBiv iQ MiB+BTi2 ?vTQ;Hv+2KBb iQ TiB2Mib MQi r2`BM; Mv BMbmHBM
TmKT Q` Mv +QMiBMmQmb ;Hm+Qb2 KQMBiQ`BM; /2pB+2X h?Bb Kv bbBbi TiB2Mib iQ
#2 +QM}/2Mi #Qmi i?2 THMM2/ BMbmHBM BMiF2X
AM (8)- _2//v 2i HX T`2b2Mi2/  #QHmb +H+mHiQ` #b2/ QM *:J /2pB+2 mbBM;
*b2@"b2/ _2bQMBM; U*"_V K2i?Q/bX h?2v 2pHmi2/ Bi r?BH2 +[mB`BM; i?2
/ib2i mb2/ BM i?Bb bim/vX h?2B` rQ`F Bb +HQb2` iQ i?2 Q#D2+iBp2b Q7 i?Bb 2tT2`@
BK2Mi i?M T`2pBQmbHv +Bi2/ `2Hi2/ rQ`FbX >Qr2p2`- i?2B` K2i?Q/ Bb #b2/ QM
*:J /2pB+2b b QTTQb2/ iQ Qm` rQ`FX
h?2 irQ /ib2ib `2 T`2b2Mi2/ BM a2+iBQM kX h?2 a2+iBQM j 2tTHBMb i?2
K2i?Q/QHQ;v M/ T`2b2Mib i?2 `2bmHib- M/ }MHHv `2bmHib Q7 i?Bb `2b2`+? `2
/Bb+mbb2/ BM a2+iBQM 9X
k .ib2ib
h?Bb rQ`F Bb #b2/ QM irQ /ib2ib,  }`bi QM2 i?i ?p2 #22M +[mB`2/ QM ivT2 A
/B#2i2b TiB2Mib- M/  b2+QM/ QM2 i?i ?p2 #22M ;2M2`i2/ #v  bBKmHiQ`X
h?2b2 irQ /ib2ib `2 T`2b2Mi2/ BM i?2 7QHHQrBM; bm#b2+iBQMbX
kXR _2H@TiB2Mib /ib2i
h?2 /i#b2 mb2/ BM i?Bb bim/v rb T`QpB/2/ #v i?2 AKT2`BH *QHH2;2 GQM@
/QM (8)X h?2 TQTmHiBQM +QMbBbib Q7 Ry TiB2Mib UK2M M/ rQK2MV- ;2/ #2ir22M
k9 M/ d9 bmz2`BM; 7`QK ivT2 A /B#2i2bX h?2 TiB2Mib ?p2 #22M 2M`QHH2/ iQ 
e@r22Fb +[mBbBiBQM b2bbBQM- /m`BM; r?B+? bQK2 Q7 i?2 TiB2MibǶ K2bm`2b ?p2
#22M +QHH2+i2/X AM //BiBQM- i?2 TiB2Mib r2`2 T`QpB/2/  KQ#BH2 TTHB+iBQM rBi?
M BMbmHBM #QHmb /Qb2 /2+BbBQM bmTTQ`i bvbi2K #b2/ QM *"_ (e)X
h?2 /2pB+2b mb2/ 7Q` ;i?2`BM; i?2 ;Hm+Qb2 H2p2Hb Q7 TiB2Mib r2`2 J2/i`QMB+
BS`Qk _2+Q`/2`bjX h?2 *:J iQQF `2/BM;b 2p2`v 8 KBMmi2b- k9 ?Qm`b  /v
Qp2` d@Ry +QMb2+miBp2 /vb- M/ i?2 mMBib mb2/ iQ K2bm`2 i?2 ;Hm+Qb2 r2`2
KKQHfHX h?2 *:J /i rb bmTTH2K2Mi2/ rBi? //BiBQMH BM7Q`KiBQM T`QpB/2/
#v i?2 TiB2Mib- bm+? b +`#Q?v/`i2b BM;2bi2/ U;V- i?2 BMbmHBM b?Qib UlV- H+Q?QH
+QMbmKTiBQM Uh`m2 Q` 6Hb2V- Q` r?2i?2` i?2 TiB2Mi T2`7Q`K2/ bQK2 T?vbB+H
+iBpBiB2b Q` MQi #27Q`2 i?2 K2HX
AMBiBHHv- i?2`2 r2`2 k9y9 HQ;#QQF 2Mi`B2b UHH i?2 TiB2Mib iQ;2i?2`VX 7i2` 
/i +H2MBM; T`Q+2bb U/m2 iQ KBbbBM; pHm2b +mb2/ #v i?2 2``Q`b Q7 i?2 ;Hm+Qb2
j ?iiT,ffrrrXT`Q72bbBQMHXK2/i`QMB+/B#2i2bX+QKfBT`Qk@T`Q72bbBQMH@+;K
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`2+Q`/2`- bmT2`~mQmb 2Mi`B2b +QM+2`MBM; b2MbQ` 2p2Mib- Q` /m2 iQ bKHH iBK2 BMi2`@
pH K2HbV- RR83 2Mi`B2b `2KBM2/X aBM+2 i?2 HQ;#QQF 2Mi`B2b `2 bbQ+Bi2/ rBi?
*:J `2+Q`/BM;b- r2 HbQ 2t+Hm/2/ HH i?2 b2[m2M+2b ?pBM; iQQ KMv KBbbBM;
/i BM i?2 *:J- H2pBM;  iQiH Q7 3NR 2Mi`B2bX
kXk aBKmHi2/ /ib2i
h?2 bBKmHi2/ /ib2i ?b #22M ;2M2`i2/ mbBM; i?2 lofS.Po hvT2 A
.B#2i2b aBKmHiQ` (d- 3)X
Ai +QMbBbib Q7 Ry pB`imH TiB2Mib- 7Q` r?QK 8yy /vb Q7 /i ?p2 #22M ;2M@
2`i2/ 7Q` 2+?X h?2 /i +QMbBbib Q7 *:J K2bm`2K2Mib 2p2`v 8 KBMmi2b rBi?
i?2 bbQ+Bi2/ [mMiBiv Q7 +`#Q?v/`i2b BM;2bi2/ M/ BMbmHBM mMBib iF2MX h?Bb
`2T`2b2Mib R8yy 2Mi`B2b T2` pB`imH TiB2Mib 7Q`  iQiH Q7 R8 yyyX h?2 M2+2bb`v
T`2@T`Q+2bbBM; ?p2 #22M /QM2 BM Q`/2` iQ +QMp2`i mMBib iQ i?2 QM2b Q7 i?2 `2H
/ib2iX JQbi r?2`2 bi`B;?i7Q`r`/ +QMp2`bBQMb- 2t+2Ti 7Q` i?2 BMbmHBM /Qb;2X
AM i?2 bBKmHi2/ /ib2i- i?2 BMbmHBM /Qb;2 `2 `2TQ`i2/ 7Q` BMbmHBM TmKTb- rBi?
i?2 7QHHQrBM; /2}MBiBQM,
AA_i = Al× 6000"q +
"bH
60
× 5× 6000"q URV
q?2`2 AA_i Bb i?2 pHm2 T`QpB/2/ #v i?2 bBKmHiQ`- Al Bb i?2 BMbmHBM mMBib r2
rMi iQ FMQr- "bH BM i?2 #bH BMbmHBM- M/ "q Bb i?2 TiB2Mib #Q/v r2B;?ibX
AM Q`/2` iQ mb2 i?2 bK2 ivT2 Q7 /i b BM i?2 `2H@TiB2Mib /ib2i iQ #2 #H2
iQ +QKT`2 `2bmHib- i?2 7Q`KmH2 ?b #2M i`Mb7Q`K2/ b 7QHHQr,
Al = AA_i× "q− "bH× 500
6000
UkV
h?2 Al pHm2 ?b i?2M #22M mb2/ b i?2 BMbmHBM BMiF2 72im`2 BM i?2 2tT2`B@
K2MibX
j J2i?Q/QHQ;v M/ _2bmHib
1+? HQ; 2Mi`v rb H#2HH2/ ++Q`/BM; iQ w2++?BM (N), i?2 ;Hm+Qb2 #2HQr dy K;f/G
UjX33N KKQHfHV rb +QMbB/2`2/ ?vTQ;Hv+2KB- r?BH2 ;Hm+Qb2 #Qp2 R3y K;f/G
URy KKQHfHV rb +QMbB/2`2/ ?vT2`;Hv+2KBc Qi?2` ;Hm+Qb2 H2p2Hb +Q``2bTQM/ iQ
i?2 MQ`KQ;Hv+2KB bii2X AM i?Bb 2tT2`BK2Mi r2 `2;`QmT2/ MQ`KQ;Hv+2KB M/
?vT2`;Hv+2KB BM i?2 bK2 +Hbb #2+mb2 r2 QMHv rMi iQ T`2/B+i ?vTQ;Hv+2KBbX
aBM+2 KQbi M/B`b Q++m` `QmM/ k ?Qm`b 7i2` BM;2biBQM Q7  +`#Q?v/`i2
K2H (Ry- N)- r2 HQQF2/ 7Q` ?vTQ;Hv+2KBb #2ir22M RX8 ?Qm`b M/ kX8 ?Qm`b 7i2`
 K2H 7Q` /2}MBM; i?2 BMbmHBM@BM/m+2/ ?vTQ;Hv+2KB +Hbb H#2HbX h?Bb `2bmHib-
b 2tT2+i2/- BM [mBi2 BK#HM+2/ /ib2ib, 3kd MQM@?vTQb 7Q` e9 ?vTQb BM i?2
`2H@TiB2Mib /ib2ib- R9 Nkj MQM@?vTQb 7Q` ed ?vTQb BM i?2 bBKmHi2/ QM2X
a2p2`H 7KBHB2b Q7 K+?BM2 H2`MBM; H;Q`Bi?Kb ?p2 i?2M #22M i`B2/ rBi? i?2
Svi?QM b+BFBi@H2`M HB#``v9, HBM2` +HbbB}2`- M2`2bi M2B;?#Q`b- `M/QK 7Q`2bi-
9 ?iiT,ffb+BFBi@H2`MXQ`;f
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2ti` i`22b M/ aoJX q2 mb2/ ivTB+H K+?BM2 H2`MBM; ;QQ/ T`+iB+2b, 2pHm@
iBQMb ?p2 #22M /QM2 rBi? Ry@7QH/b +`Qbb@pHB/iBQM- rBi?BM 2+? +`Qbb@pHB/iBQM
HQQT i?2 KQ/2Hb T`K2i2`b ?p2 #22M }M2@imM2/ rBi?  +`Qbb@pHB/i2/ ;`B/@
b2`+? QM i?2 i`BMBM; b2i- M/ i?2 +Hbb2b r2B;?ib ?p2 #22M b2i iQ +QKT2Mbi2
i?2 +Hbb BK#HM+2X
h?2 b2H2+iBQM Q7 i?2 b+Q`BM; K2i?Q/ Bb  KQ`2 bm#D2+iBp2 ibFX h?2 ++m`+v
HQM2 Bb MQi mb27mH QM BK#HM+2/ /ib2ib #2+mb2 Mbr2`BM; Hrvb i?2 K@
DQ`Biv +Hbb ;Bp2b ?B;? b+Q`2b rBi?Qmi #2BM; mb27mH i HHX S`2+BbBQM M/ _2+HH
#Qi? ?p2 i?2B` miBHBivX S`2+BbBQM `2Hi2b iQ i?2 MmK#2` Q7 7Hb2 H`Kb- r?B+? Bb
BKTQ`iMi iQ F22T TiB2Mib /?2`2M+2 iQ i?2 bvbi2KX _2+HH `2Hi2b iQ i?2 T2`@
+2Mi;2 Q7 /2i2+i2/ ?vTQ;Hv+2KBb- M/ r2 `2 i`vBM; iQ pQB/ ?vTQ;Hv+2KBb bQ
BiǶb BKTQ`iMi iQ /2i2+i i?2 KtBKmK MmK#2` Q7 i?2KX h?2 6R b+Q`2 ?b #22M
b2H2+i2/ b Bi ;Bp2b i?2 ?`KQMB+ K2Mb #2ir22M T`2+BbBQM M/ `2+HH- #mi i?Bb
+?QB+2 Qp2` Qi?2` b+Q`BM; K2i?Q/ Bb `#Bi``vX
h#H2 RX 6R b+Q`2b
H;Q`Bi?K SiB2Mib /ib2i US`BQ`4RjX9V aBKmHi2/ /ib2i US`BQ`4yX3NV
GBM2` +HbbB}2` RyXNj RXR8
L2`2bi M2B;?#Q`b 8Xde yX88
_M/QK 7Q`2bi kX9R yX8y
1ti` i`22b eXdk yX83
aoJ RjXdy yX3R
h?2 T`BQ` 6R@b+Q`2 Q7 i?2 `2H@TiB2Mib /ib2i Bb RjX9W M/ i?2 #2bi `2@
bmHi Bb Q#iBM2/ rBi? i?2 aoJ +HbbB}2`- r?B+? +?B2p2b RjXdWX h?2 KDQ`Biv
Q7 MQM@?vTQb `2 +HbbB}2/ +Q``2+iHv- b r2HH b i?2 KDQ`Biv Q7 ?vTQb i?i `2
HbQ +HbbB}2/ +Q``2+iHvX h?2 MmK#2` Q7 7Hb2@H`K M/ i?2 MmK#2` Q7 KBbb2/
?vTQ;Hv+2KBb T`2p2Mi Mv TTHB+iBQM BM `2H@rQ`/ i?Qm;?X PM i?2 bBKmHi2/
/ib2i i?2 `2bmHib `2 MQi `2HHv #2ii2`, i?2 T`BQ` 6R@b+Q`2 Bb yX3NW M/ i?2
HBM2` +HbbB}2` +?B2p2b  b+Q`2 Q7 RXR8WX h?Bb /Q2b MQi HHQr 2Bi?2` Mv mb2 BM
`2H@rQ`H/ b+2M`BQbX
9 .Bb+mbbBQMb
h?2 #2bi `2bmHib Q#iBM2/ QM i?2 TiB2Mib /ib2i `2 bHB;?iHv #2ii2` i?M i?2
/ib2i T`BQ`b- #mi `2 MQi ;QQ/ 2MQm;? iQ #2 mb2/ BM Mv `2H@rQ`H/ TTHB+iBQMX
PM2 TQBMi i?i ?p2 #22M MQi2/ r?BH2 rQ`FBM; QM i?Bb /ib2i `2 mM2tTHBM2/
;Hm+Qb2 T2Fb- M/ i?2 KQbi HBF2Hv +mb2 Q7 i?Bb b?QmH/ #2 KBbbBM; +`#Q?v/`i2b
BM7Q`KiBQMX MQi?2` `2Hi2/ r2F TQBMi Q7 bm+? `2H@HB72 /ib2i Bb i?2 7+i i?i
++m`i2 +`#Q?v/`i2b 2biBKiBQMb `2 /B{+mHiX AM Q`/2` iQ 2pHmi2 B7 i?2b2
~rb Kv #2 2tTHBMBM; i?2 /B{+mHiB2b Q7 T`2/B+iBQM QM i?2 `2H@TiB2Mib /ib2i-
r2 `2T`Q/m+2/ i?2 bK2 2tT2`BK2Mi QM i?2 bBKmHi2/ /ib2iX
h?2 2tT2`BK2Mi QM i?2 bBKmHi2/ /ib2i- /Q2b MQi b22K iQ Qz2` bB;MB}+Mi
BKT`Qp2K2MibX "2BM; ;2M2`i2/ #v  bBKmHiQ`- i?2 /i b?QmH/ ?Qr2p2` #2?p2
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KQ`2 T`2/B+iBp2Hv i?M  ?mKM #Q/v #2+mb2 i?2 ?mKM #Q/v Bb Km+? KQ`2
+QKTH2t M/ Bb b2MbB#H2 iQ i?2 2ti2`MH 2MpB`QMK2MiX h?2 bBKmHiQ` Bb HbQ ;BpBM;
i?2 2t+i M/ +QKTH2i2 b2i Q7 +`#Q?v/`i2b M/ BMbmHBM BMiF2b- BM +QMi`bi iQ
?mKM MMQiiBQMbX
h?Bb 2tT2`BK2Mi bmTTQ`ib }`bi i?i i?2 r2FM2bb BM TiB2Mib MMQiiBQMb
HQM2 Bb MQi 2MQm;? iQ 2tTHBM i?2 /B{+mHiB2b Q7 ?vTQ;Hv+2KBb T`2/B+iBQM- Qi?@
2`rBb2 ;QQ/ `2bmHib rQmH/ ?p2 #22M `2+?2/ QM i?2 bBKmHi2/ /ib2iX a2+QM/-
i?2 #b2M+2 Q7 #2ii2` `2bmHib QM i?2 bBKmHi2/ /ib2i- /2bTBi2 ?pBM; #22M i2bi2/
rBi? /Bz2`2Mi 7KBHB2b Q7 K+?BM2 H2`MBM; H;Q`Bi?Kb- b?Qrb i?i i?2 72im`2b
mb2/ U;Hm+Qb2 H2p2Hb- BMbmHBM BMiF2b M/ +`#Q?v/`i2b 2biBKiBQMbV +M MQi T`2@
/B+i ?vTQ;Hv+2KBb b@BbX h?Bb /Q2b MQi K2M ?Qr2p2` i?i i?2 T`Q#H2K Kv
MQi #2 bQHp2/ i?`Qm;? 7m`i?2` 72im`2b 2M;BM22`BM; Q` #v mbBM; KQ`2 +QKTH2t
KQ/2HbX  KQ`2 /2iBH2/ bim/v Q7 i?2 72im`2b M/ KQ/2Hb rQmH/ ?2HT iQ B/2MiB7v
i?2 7+iQ`b BMpQHp2/ BM i?2 /B{+mHiB2b Q7 bm+? T`2/B+iBQMb- M/ rQmH/ T2`KBi iQ
T`QTQb2 ;mB/2HBM2b 7Q` BKT`QpBM; i?2 +[mBbBiBQM Q7 M2r hvT2 A /B#2i2b /ib2ibX
_272`2M+2b
RX SH2`K- *X*X- M/ "2[m2ii2- "XqX, >vTQ;Hv+2KB /2i2+iBQM M/ T`2/B+iBQM mbBM;
+QMiBMmQmb ;Hm+Qb2 KQMBiQ`BM;ě bim/v QM ?vTQ;Hv+2KB+ +HKT /iX UkyydV
kX 1`2M@P`mFHm- JX- *BM`- X- M/ ZmBMM- GX, >vTQ;Hv+2KB T`2/B+iBQM rBi? bm#D2+i@
bT2+B}+ `2+m`bBp2 iBK2@b2`B2b KQ/2HbX UkyRyV
jX >m;?2b- *XaX- Si2F- aX.X- "`2iQM- JX.X- M/ EQpi+?2p- "XSX, >vTQ;Hv+2KB T`2@
p2MiBQM pB TmKT ii2MmiBQM M/ `2/@v2HHQr@;`22M ǳi`{+Ǵ HB;?ib mbBM; +QMiBM@
mQmb ;Hm+Qb2 KQMBiQ`BM; M/ BMbmHBM TmKT /iX CQm`MH Q7 /B#2i2b b+B2M+2 M/
i2+?MQHQ;v 9U8V- RR9eĜRR88 UkyRyV
9X "m+FBM;?K- "X- *Q#`v- 1X- *HBMiQM- SX- :;2- oX- *br2HH- EX- EmMb2HKM- 1X-
*K2`QM- 6X- M/ *?b2- >XSX, S`2p2MiBM; ?vTQ;Hv+2KB mbBM; T`2/B+iBp2 H`K
H;Q`Bi?Kb M/ BMbmHBM TmKT bmbT2MbBQMX .B#2i2b i2+?MQHQ;v  i?2`T2miB+b RRUkV-
NjĜNd UkyyNV
8X _2//v- JX- S2bH- SX- s2MQm- JX- hQmKxQm- *X- CQ?MbiQM- .X- :2Q`;BQm- SX- >2``2`Q-
SX- M/ PHBp2`- LX, *HBMB+H a72iv M/ 62bB#BHBiv Q7 i?2 /pM+2/ "QHmb *H+mHiQ`
7Q` hvT2 R .B#2i2b "b2/ QM *b2@"b2/ _2bQMBM;,  e@q22F LQM`M/QKBx2/
aBM;H2@`K SBHQi aim/vX .B#2i2b h2+?MQH h?2` R3- 93dĜ9Nj UkyReV
eX KQ/i- X- M/ SHx- 1X, *b2@#b2/ `2bQMBM;, 6QmM/iBQMH Bbbm2b- K2i?Q/@
QHQ;B+H p`BiBQMb- M/ bvbi2K TT`Q+?2bX A +QKKmMB+iBQMb dURV- jNĜ8N URNN9V
dX JM- *X.X- JB+?2H2iiQ- 6X- Gp- .X- "`2iQM- JX- EQpi+?2p- "X- M/ *Q#2HHB- *X,
h?2 lofS.Po ivT2 R /B#2i2b bBKmHiQ`, M2r 72im`2bX CQm`MH Q7 /B#2i2b
b+B2M+2 M/ i2+?MQHQ;v 3URV- keĜj9 UkyR9V
3X oBb2MiBM- _X- .HH JM- *X- EQpi+?2p- "X- M/ *Q#2HHB- *X, h?2 lMBp2`bBiv Q7
oB`;BMBfS/Qp ivT2 R /B#2i2b bBKmHiQ` Ki+?2b i?2 ;Hm+Qb2 i`+2b Q7  +HBMB+H
i`BHX .B#2i2b i2+?MQHQ;v  i?2`T2miB+b ReUdV- 9k3Ĝ9j9 UkyR9V
NX w2++?BM- *X, PMHBM2 :Hm+Qb2 S`2/B+iBQM BM hvT2 R .B#2i2b #v L2m`H L2irQ`F
JQ/2HbX lMBp2`bBi¨ /2;HB aim/B /B S/Qp UkyR9VX
RyX "`mM- CX6X- 62/Qm- *X- M/ J2`+B2`- CX, SQbiT`M/BH `2+iBp2 ?vTQ;Hv+2KBX .B@
#2i2b  J2i#QHBbK keU8V- jjdĜj8R UkyyyV
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Abstract. Diabetes has several secondary complications. In this paper
we study Diabetic Retinopathy, which consists of the split of some blood
vessels on the eye, causing a blur vision or even blindness. Early detection
may improve significantly the treatment of this disease and minimize its
consequences on the vision loss. For this reason, we are working with
a Catalan hospital to build a Clinical Decision Support System to help
family physicians to estimate the risk of developing diabetic retinopathy
using the information they obtain in the regular visits done to a diabetic
patient. Such system may improve the diagnosis in Primary Health Care
centers, which enables a better scheduling of other screening tests like the
inspection of the eye’s fundus with cameras, which is done in specialized
ophthalmologist services.
1 Introduction
Diabetic retinopathy (DR) is one of the main complications of diabetes, be-
ing a common cause of blindness for this kind of patients. A Clinical Decision
Support System (CDSS) is being developed in order to help clinicians to esti-
mate the risk of developing diabetic retinopathy as early as possible. It is called
RETIPROGRAM. Such system may improve the diagnosis in Primary Health
Care centers, reducing the workload of ophthalmologist services. Nowadays, all
diabetic patients are screened every two years by taking images of the eyes’ fun-
dus. Lesions in the eye can be detected in those images, being the main source
for DR diagnosis. However, using a fixed time for screening is not an appropriate
model because there are cases in which retinopathy will be detected too late,
while there are many patients that do not require this screening because the
disease will not appear. In a study made with the patients of the area of South
Catalonia (from 2007 to 2014) [2], it was observed that incidence was stable be-
tween 2007 and 2011 (around 8.1%) but since 2011 it has continuously increased
until almost 9%. It has also been observed that it is still increasing and it will
probably be around 10% in 2020. If the screening focuses on this small subset of
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the population, resources would be used in a more cost-effectively way. In fact,
in [3] a study of the cost of screening shows that it can be reduced by a person-
alized screening timing based on each patient’s risk factors. This information is
systematically gathered in the Electronic Health Record (EHR). Thus, the goal
is that the CDSS can use data from the EHR to decide when to make the eye
analysis, focusing the use of resources on the patients that really need them. In
that way, we can avoid unnecessary screenings on patients, saving the time of
doctors and patients.
2 Methods
The system is now under development but the plan is to integrate it in the
software tools managed in the Health Care Centers of Catalonia (Spain). The
system will get information directly from the databases and will use the patient’s
data to make an estimation of the risk of developing DR.
GRÀFIC O IMATGE
Patient with Diabetes
Mellitus arrives for 
control visit
Health Care Center Primary care physician
Checks patient’s
conditions. 
Stores in EHR
The computer system estimates 
the risk of Diabetic Retinopathy
If there is low or no risk, then a new visit is programmed for 3 years
Primary care physician
Gets an image of the eye with 
a non-mydriatic camera
The computer analyses the image 
and a new estimation is done with 
clinical data and the image features 
Ophthalmologist
Diagnosis confirmation
and treatment actions
If there is low or no risk, then a 
new visit is programmed for 1 
or 2 years
If the risk is 
moderate or high, 
or if doubt
If the risk is 
moderate or 
high, or if 
doubt
Fig. 1: CDSS architecture for the diagnosis of the risk of DR on the diabetic
patients
Figure 1 shows the architecture of the CDSS. It consists of six steps. First,
the patient is visited in the Health Care center by a family doctor. If the patient
is diabetic, the doctor will use the RETIPROGRAM to get the values of some
relevant attributes from the patients EHR. Third, a set of fuzzy decision rules
are applied to calculate the risk of DR. If the risk is low, the next visit of the
patient is scheduled for two or three years. If risk is moderate or high, a photo
of the eyes’ fundus is taken using a non-mydriatic camera. This test is neither
invasive nor painful, but it needs to be done by a specialist because the light
and calibration conditions are very important to get a good image. This image
is then fed into the RETIPROGRAM. The system then applies computer vision
techniques to automatically detect any kind of lesion in the eye, especially those
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near the macula. This information is displayed to the doctor and the next visit
is scheduled according to the DR risk level. In fact, if lesions are found, the risk
will be set to a high level and an urgent appointment with an ophthalmologist
will be programmed. Up to now, there is no CDSS with these characteristics.
Although there exist some works on the assistance of RD detection using com-
puter vision techniques, there are no tools that also integrate the analysis of
the information in the Electronic Health Record due to the lack of a systematic
collection of all data from patients. Since 2007 several analytical, metabolic and
demographic data have been systematically collected and stored in the EHR of
patients treated at Sant Joan de Reus University Hospital (Catalonia, Spain).
This hospital serves an area of Catalonia with a population of 247,174 inhab-
itants, having 17,792 patients with Diabetes Mellitus. The goal of the current
research project is to develop this CDSS. Developing such kind of system needs
the use of different Artificial Intelligence techniques. RETIPROGRAM includes
two main components:
PART 1. Analysis of the EHR
Due to the uncertainty present in the data and the suitability of linguistic
models, a system based on fuzzy linguistic rules is being constructed. The iden-
tification of 9 relevant attributes for the diagnosis of DR was done in [2]. Using a
dataset with around 2,000 patients we have trained and tested different models.
The construction of a single fuzzy decision tree was proposed in [5]. To improve
the classification accuracy, an ensemble of classifiers has been obtained using a
Fuzzy Random Forest [4]. The rules generated indicate that the most relevant
attributes are hypertension, medication and age. As the number of records is
not large, we have cases in which the lack of examples makes the diagnosis of
DR unfeasible. This case is communicated to the user.
PART 2. Analysis of the eye fundus images
Diabetic Retinopathy causes blindness due to the dilatation of small blood
vessels (microaneurysms) which produces intra-retinal haemorrhages and fluid
leaking composed by lipoproteins and lipids (exudates). In order to detect these
lesions in a 2D image, it is necessary to first remove the normal structures of
the eye (blood vessels, optic disc). Until now, we have explored two algorithms
(Convexity Shape Prior and GrabCut) for the segmentation [1]. This cleaning of
the image should allow us to leave in the image only the pathological elements
and the image background color. In an ongoing study, the Convexity Shape Prior
method is also being used to locate the macula, because lesions near the macula
are the ones that cause blindness. Then, some techniques for identification and
counting of the types of lesions will be needed.
Finally, the features extracted with the image processing should be later
analyzed together with the EHR data, to improve the accuracy of the system.
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3 Conclusions and research challenges
The results obtained up to now give us confidence in the possibility of construct-
ing a powerful decision support system for estimating the risk of developing di-
abetic retinopathy. Building this CDSS presents some research challenges that
we should address: (1) the integration of different methods of rule construction
seems necessary as the current results only achieve a sensitivity and specificity of
80%; (2) the dataset is highly imbalanced (with less cases of patients with DR)
and this fact requires of special training techniques, both for rule induction as
well as for image processing; (3) the combination of the features extracted from
the images with the attributes of the EHR must be studied; (4) the applicability
of RETIPROGRAM in different populations should also be carefully considered
to validate the system.
Therefore, there are still some important open questions to work on before
deploying the system into real use.
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Abstract. Artificial Intelligence (AI) is potentially useful for cost e↵ec-
tive diabetes self-management. One research priority for the development
of robust and beneficial AI concerns the use of formal verification tech-
niques to model such self-modifying systems. In the context of diabetes,
formal methods may also have a role in fostering trust in the technology
as well as facilitating dialogue between a multidisciplinary team to deter-
mine system requirements in a precise way. In this paper we show how the
formal modelling language Event-B can be used to capture safety-critical
constraints associated with AI systems for diabetes management.
1 Introduction
Most people with Type 1 Diabetes (T1D) have to perform complex insulin dose
calculations several times a day. The computations must consider multiple fac-
tors and can occur in a variety of contexts that might a↵ect cognitive load.
Adaptive solutions that use artificial intelligence (AI) to replace this human
decision-making are emerging [5, 6], but the application of such technology to
safety-critical healthcare problems is often met with high levels of resistance
[4]. Individuals are concerned about loss of control and question whether the
perceived risk is outweighed by the potential benefit.
Such systems must therefore behave robustly and deliver the intended bene-
fits consistently in order to foster trust. Some computer science research priorities
that have been identified towards this goal include formal verification and vali-
dation [7]. Although features of AI systems, such as nondeterminism, can make
them di cult to verify, it should be possible to build them from individual com-
ponents that have been proved correct. Additionally, they might be used within
the confines of a deterministic safety systems that have been formally verified.
Another dimension is introduced by the user interface of AI systems. Tools
exist to support the formal design and analysis of human-machine interfaces,
including the behaviour of objects such as buttons and keyboards [3]. Such tech-
nologies can be used to give a lightweight, formal analysis of the safety require-
ments of the interface. They may therefore have a role in facilitating dialogue
between a multidisciplinary team, which could include clinicians and computer
scientists, in evolving a common understanding of these requirements in a precise
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way. In this paper we present a simplified formal specification of part of a T1D
bolus recommender system in an attempt to show how some properties might be
expressed. This might form part of a model that a trustworthy AI system must
guarantee not to violate.
2 Formal Specification
Event-B is a formal modelling language developed by Jean-Raymond Abrial as an
evolution of the B-Method [1]. The purpose of modelling with Event-B is to prove
that a model will work prior to implementation and for early identification of
problems with the system requirements. The Rodin Platform is an Eclipse-based
integrated development environment (IDE) for Event-B modelling. It has an
associated repository of resources to aid existing and new users of the platform,
including a plug-in to integrate ProB into the IDE, which provides a method
to systematically check the model for errors through animation. Other plug-ins
include automated code generation from the Event-B specification and external
provers to assist the automatic proofs. For example, the Atelier B prover plug-in
was used in the work described below.
An Event-B model is validated through the successful discharge of proof
obligations, which imply that the invariants and type declarations of the model
are not violated by any aspect of the model. For example, if a variable x has type
N1, the assignment of 0 to x would fail to discharge the proof obligation created
by x 2 N1 since x must be greater than or equal to 1. A key feature of the Event-
B language is its incremental modelling process through refinement. Refinement
allows gradual development of the specification starting at an abstract level,
which can then be refined to include new functionality and gradually move the
model towards the concrete implementation.
2.1 Event-B Specification of T1D System Constraints
The specification begins with an abstract specification of the system, focussing
on the constraints of the system variables. Figure 1 provides an extract of the
variables and invariants that includes the maximum bolus dose, and upper and
lower target blood glucose ranges. A full specification of the variables and in-
variants is included in [2]. Event-B is limited to natural and integer numerical
types, which presents a problem when decimal values are required. To overcome
this, all natural numbers or integers in the specification are represented through
multiplication by the power of 10, allowing precision to one decimal place (e.g.
5.5 is represented as 55). Comments in the specification will be used help to
reinforce this representation.
The types of maxBolus, targetRangeUpper and targetRangeLower are de-
fined in Figure 1 as natural number (N). This invariant alone implies that the
value of these variables must be greater than or equal to 0, and that negative
values are not permitted. inv2 states that maxBolus is restricted to a maxi-
mum bolus value of 50.0 and inv7 ensures that the target range is non-empty.
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MACHINE t1dm m0
VARIABLES
maxBolus Maximum bolus dose limit
targetRangeUpper Target blood glucose range upper value
targetRangeLower Target blood glucose range lower value
INVARIANTS
inv1 : maxBolus 2 N
inv2 : maxBolus  500
The maximum bolus dose must be in the range [0.0,50.0] IU
inv3 : targetRangeUpper 2 N
inv4 : targetRangeUpper   55 ^ targetRangeUpper  150
Target blood glucose range upper value must be in the range [5.5,15.0]
inv5 : targetRangeLower 2 N
inv6 : targetRangeLower   30 ^ targetRangeLower  80
Target blood glucose range upper value must be in the range [3.0,8.0]
inv7 : targetRangeLower  targetRangeUpper
Target blood glucose range upper value must be in the range [3.0,8.0]
Fig. 1. Extract of machine variables and invariants
Both of the invariants for maxBolus state that 0  maxBolus  50 insulin
units. Additionally, the invariants for targetRangeUpper and targetRangeLower
also define the constraints: 5.5  targetRangeUpper  15.0 mmol/L, and
3.0  targetRangeLower  8.0 mmol/L. These invariants prevent the vari-
ables from breaching the constraints imposed by the Accu-Chek R  Aviva Expert
blood glucose meter.
MACHINE t1dm m0
EVENTS
Event bolusCalc b=
Bolus calculator event for instances where s is > 0 and < maxBolus
any
s
s is the parameter of bolus suggestion
where
grd1 : s 2 N
grd2 : s  maxBolus
The bolus solution suggestion is  maxBolus
then
act1 : bolusSuggestion := s
Sets the bolus suggestion value to parameter s
end
Fig. 2. Abstract bolus calculation event
An abstract event for the bolus suggestion bolusCalc is described by Figure 2.
One parameter is specified for the event, the bolus suggestion s. The event has
two guards which check that parameter s is a natural number and that s is less
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than or equal to the maximum bolus dose maxBolus:
bolusSuggestion 2 N ^ bolusSuggestion  maxBolus
The bolusCalc event does not satisfy the requirements of the application alone
as it is possible that the bolus suggestion may be negative or greater than the
maximum bolus dose. In these circumstances, the bolus dose should be set to 0
and the maxBolus respectively. To model this, two new events are added to the
model to allow for these circumstances bolusCalcNeg and bolucCalcMax. These
events are shown in Fig. 3.
MACHINE t1dm m0
EVENTS
Event bolusCalcNeg b=
Bolus calculator event for instances where s is < 0
any
s
s is the parameter of bolus suggestion
where
grd1 : s 2 Z
grd2 : s < 0
The bolus solution suggestion is < 0
then
act1 : bolusSuggestion := 0
Sets the bolus suggestion to 0 as negative values are not permitted
end
Event bolusCalcMax b=
Bolus calculator event for instances where s is > maxBolus
any
s
s is the parameter of bolus suggestion
where
grd1 : s 2 N
grd2 : s > maxBolus
The bolus solution suggestion is > the maximum bolus dose
then
act1 : bolusSuggestion := maxBolus
Sets the bolus suggestion to maxBolus as values > maxBolus are not
permitted
end
Fig. 3. Additional abstract bolus calculation events
At present, the model does not include the computation to be performed
to determine the bolus dose, but instead defines the abstract events required.
This abstract model can now be refined into a more concrete one. In [2] it is
refined to include a case base and deterministic bolus calculator. All proofs are
automatically discharged by the prover and animation with ProB indicates that
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the events are only activated by parameters which satisfy the guards. The same
technique could be applied to the refinement for a nondeterministic calculator
including AI.
3 Conclusion
This short example illustrates how critical safety constraints of a T1D bolus cal-
culator involving AI can be captured formally. We believe that the construction
of a validated, definitive core task model for the T1D individual and associated
recommender system, verified using formal techniques, should be a research pri-
ority for artificial intelligence in diabetes. However, there are more di cult chal-
lenges related to the ability to verify AI systems that modify themselves, possibly
repeatedly, over time. It is not yet known whether straightforward verification
tools can be applied to this broader setting [7].
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Abstract.
This paper proposes a new biologically-inspired phenomenological model
of insulin release that can be used to continuously monitor a person with
diabetes and therefore recommend insulin dose and predict events. Given
all the parameters and conditions that have to be met in order to achieve
stability, the proposed insulin-release system will be considered as highly
non-linear and dynamical. The resulting model will study the mechanisms
that keep the system from reaching a chaotic state (diabetes), based on
the property of self-organised criticality. This property was selected since
it has been previously identified and studied in other dynamical biological
systems. The proposed model will then be used as part of a model-based
reasoning system that aims to support patients with diabetes.
1 Introduction
Regulation of insulin and glucose in the human body is part of a complex dy-
namical system, whose understanding and study is highly relevant for the man-
agement of diabetes. This system is in turn influenced by factors such as meal
intake, heart rate, exercise, sleep, and other factors. Research and development
on the insulin release system, also known as the artificial pancreas, can be traced
back at least 50 years [1]. The models, signals, and control algorithms involved
in the design of the insulin-release clinical system are the three most relevant
areas of study. This research has facilitated the advancement of continuous glu-
cose monitoring technologies, and the development of medical devices that assist
type 1 diabetic patients in self-management of their condition.
Significant improvements have been made in continuous glucose monitoring
technologies, and several control techniques have been tested and implemented
on medical devices. However, in the context of modelling, it was found that a
significant discrepancy exists between the physiological understanding and the
low-level mechanisms that permit the physiological state [2]. This finding is the
main motivation for the development of the model proposed in this paper. The
modelling approach will be improved by studying the phenomenological aspects
of insulin release using mathematical properties.
This paper summarizes the preliminary research that was conducted, as well
as the modelling approaches that will be considered in order to construct the
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research proposal. The model will then be used to identify how individual dia-
betes patients are influenced by di↵erent factors such as carbohydrate intakes,
hormones, physical exercise and so on, and therefore support them in their re-
quired insulin doses.
2 Preliminary research on Bio-Inspired Models
To better understand the features of the model proposed in this research, physi-
ological and mathematical models were studied. Among the physiological mod-
els analysed, minimal and maximal models were identified as the main models
considered for CGM technology development. For the purpose of this research
project, further studying of the phenomenological aspects of insulin-release us-
ing mathematical properties will be conducted. This was decided given a few
misrepresentations found in physiological models, which are briefly also detailed
in this section.
2.1 Physiological models
A physiological model is defined as the qualitative or quantitative representa-
tion of an actual physiological system. Quantitative physiological modelling is
preferred, and considered to be more useful, as it provides a mathematical rep-
resentation characterized by di↵erential equations [5]. The most commonly used
approach for the artificial pancreas system is compartmental modelling [4], a spe-
cial case of physiological modelling where the movement of a substance between
compartments is described. Furthermore, there are two classes of physiologically-
based models for the artificial pancreas system, both described in this section:
maximal models and minimal models.
Minimal models focus on explaining the key components of the system and
measuring essential processes involved in healthy state and diabetes. One of the
earliest models documented is the one developed by Bergman and colleagues back
in the 70s [1]. The aforementioned model has undergone several modifications
to include additional compartments and incorporate the e↵ects of disturbances
such as meal or exercise. Other examples of minimal models include the com-
partmental approaches proposed by Insel, et. al. and Cobelli et. al. in [2] which
attempt to measure and understand glucose metabolism and its regulation by
insulin.
Maximal models attempt to simulate the glucose insulin system using all
available knowledge of functionality, thus allowing the researcher to carry out
experiments in particular scenarios [3]. Useful information on the general func-
tions of the system has been collected. One of the most representative examples
is that of the GIM (Glucose Insulin Model) simulation software, which was de-
signed based on the model proposed by Chiara Dalla Man, Robert A. Rizza, and
Claudio Cobelli [4], consisting of 12 di↵erential equations and 35 parameters.
This software has been useful to simulate healthy state subjects, type 2 diabetic
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subjects, and impaired glucose-tolerant subjects in two main scenarios: meal
and daily life. The model developed by Grodzky, Jonkers and Henquin [9], was
able to demonstrate the number of active cells is a sigmoidal function of glucose
concentration, and suggest that insulin release is subject to di↵erent thresholds .
Minimal models are commonly used to analyse the data obtained from glu-
cose tolerance tests. Although the results obtained prove useful, they tend to
misrepresent the actual dynamics of the glucose-insulin system given that they
are modelled in steady state. Some misrepresentation is also observed in maxi-
mal models, given that several of the parameters used in the system are derived
from steady-state conditions.
Several other studies have been conducted in an attempt to understand the
insulin release phenomenon in the human pancreas, these include glucose toler-
ance tests and in vitro studies (see [2] and [9]).
After revising the state-of-the-art in physiological modelling for the artificial
pancreas, it was concluded that these models alone would not be su cient for
the development of this research project. The studied models have been able
to provide useful information about the phenomenon of insulin release in the
pancreas, and they provide solid evidence of progress in the field. However, it is
considered that the models do not accurately represent the physiological state
as they provide a generalized mathematically reduced approach, rather than a
detailed representation on the dynamics of insulin-release. It was thus decided
to explore a di↵erent set of methods to further develop the research project.
These are presented in the subsequent section of this article.
2.2 Computational models and properties
This section introduces the property of self-organized criticality, Turing mech-
anisms, and two reaction-di↵usion systems that will be considered as the foun-
dation for the development of the model. These properties and systems have
been chosen since they have been previously studied and identified in biological
systems. While physiological models focus on representing the physical inter-
actions of the system, the following systems and properties focus on describing
complex mathematical scenarios, such as chemical reactions and/or the interac-
tion between an activator and an inhibitor.
The property of self-organized criticality is particular to dynamical systems
that are attracted to a critical point; for the past decade it has been identified
and studied in biological systems. It has proven useful in defining and under-
standing neuronal communication, the functionality of protein families, pattern
formation in biological systems, among others [11].
Turing mechanisms have been useful in research related to pattern formation,
particularly in biological patterns such as the scales of fish, the formation of a
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foetus and, at a more molecular level, pattern formation in cellular slime mould
and calcium activity [7]. The model which can assist in studying these mecha-
nisms is the two-variable Lengyel-Epstein model; a model for the photosensitive
chlorine dioxide-iodine-malonic acid reaction (CDIMA). It has proven useful for
investigating the continuous e↵ect of external influence on Turing pattern for-
mation. (see [7] and [8])
Reaction-di↵usion systems and models are also used to describe pattern for-
mation phenomena (including Turing patterns), particularly in systems that in-
volve the interaction of many components. The model of interest for the purpose
of this project is the Gray-Scott model, given the wide range of spatio-temporal
dynamics it supports [10]. This model describes auto-catalytic chemical reac-
tions of type: A + 2B ! 3B ; B ! C, where the first equation represents an
auto-catalytic process. It is possible to observe a wide range of dynamics when
the input to the reactor is a continuous uniform flow of species A. The system
can have up to three homogeneous steady-states: one trivial, and two non-trivial.
Another system of interest is the Brusselator. This system represents the
interaction between a reactor and an inhibitor, and is nowadays considered one
of the simplest reaction-di↵usion systems capable of generating complex spatial
patterns [13]. The proposed activator-inhibitor interaction is a well-known prin-
ciple to explain pattern formation in chemical, ecological, physical, and biological
systems.
3 Criticality analysis of the insulin-release system
Three possible approaches to improve the modelling methodology were identified
during the preliminary research stage. The approaches were identified based on
findings from physiological models that indicate the presence of criticality in the
system. The approaches are described in the following subsections and will have
to be analysed and simulated in order to fulfil the aim of the research project.
3.1 Finding 1: Non linearity and dynamical requirements
In mathematical terms, the insulin release system has to be considered as highly
non-linear and dynamical. Given all of the parameters involved and the condi-
tions needed to reach stability, it qualifies as one of the dynamical systems that
is attracted to a critical point, this critical point being a normal glucose level.
The low- level mechanisms of insulin release which control the system so that it
does not become chaotic (diabetes), have to be studied to gather a wider knowl-
edge on the e↵ect they have over the global state of stability [12]. This will be
achieved by studying the property of criticality observed in the insulin-release
system.
AID 2017 Proceedings of the 2nd International Workshop on Articial Intelligence for Diabetes (AID)
44
3.2 Finding 2: Identification of critical patterns
A recent study has found that local feedback has a direct e↵ect on the orien-
tation of the Turing pattern in a system, and can change the global or local
dynamics in it [7]. These findings can assist in understanding and defining the
communication mechanisms followed by beta cells which lead to the release of
insulin. This will be achieved by adding constraints to the insulin-release sys-
tem, such as thresholds and external stimuli (e.g. meal and exercise). By adding
these disturbances to the system, it will be possible to observe the e↵ect on the
insulin-release pattern, and whether or not it converges to a critical point.
3.3 Finding 3: Insulin delivery as a wave function
In the study by Jonkers and Henquin [9] it was demonstrated how beta cells
are recruited in accordance with the sensed concentration of glucose, given that
they have di↵erent threshold sensitivities to it. The study also shows how the
behaviour of a single cell can be extrapolated to the behaviour of the islet (clus-
ter) it is associated with. This property can indicate that the propagation of
insulin secretion behaves as a wave function. The control of such a system has
been studied by Y. N. Kyrychko et. al [10]. Where an activator/inhibitor control
was applied on a Gray-Scott model based system, convergence to stability was
achieved regardless of the chaotic nature of the system.
In the following stage of development, the low level mechanisms of insulin
release will be simulated to observe their influence on stability at a global level.
This will be achieved using coupled oscillators to represent the interaction of
pancreatic  -cells, which represents the foundation for the development of the
proposed model.
4 Bio-Inspired Model-Based Reasoning
In model based reasoning, an explicit model of the behaviour of the system is
used to predict its reaction given a set of initial conditions and constraints. The
predicted behaviour is then compared with the actual system and if discrep-
ancies are found and assuming that the model is accurate then the reasoning
mechanism can adapt the model to detect and identify the discrepancies. Ac-
cording to Herrero et al, [6] model-based reasoning has been proposed in di↵erent
areas related to diabetes: Safety of monitoring devices, artificial pancreas, and
prediction of hypoglycaemia.
In this research we propose to use a dynamic bio-inspired mathematical model
to better model patient assimilation of glucose. The model will then be part of
a MBR system that will be used to monitor a patient, detect when insulin is
needed and identify the doses required.
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The simulation and validation of the model will be performed using real
patient data, which will be facilitated given the collaboration with Pepper project
EU (http://www.pepper.eu.com/)
5 Conclusion
This paper proposes the development of a bio-inspired mathematical model of in-
sulin release. Three approaches to assist in studying the property of criticality in
the insulin-release system have been identified, and will be considered to develop
the model. There is no evidence suggesting that the mathematical properties
and models listed in this document have been used to model the phenomeno-
logical aspects of insulin release in the pancreas. A major advantage of using
them is their capability of explaining complex dynamical systems using a simpler
mathematical approach. Implementing this novel methodology could help fill in
some gaps in physiological modelling, such as the inclusion of disturbances and
non-linearities present in the system.
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